Hospital
Methodist Healthcare - Memphis Hospitals
Methodist Healthcare - Memphis Hospitals was paid $105.90M by Medicaid between Jan 2018 and Dec 2024, across 358 billing codes. Its largest line is 99284, emergency room visit (serious) — 40% of everything it billed.
33Billing provider infoMETHODIST HEALTHCARE - MEMPHIS HOSPITALS
MEMPHIS, TN 38104
MEMPHIS, TN 38104
33aNPI1558365890assigned 06/01/2005
33bProvider typeChildren's Hospital
28Total paid$105.90M
24GClaims2,803,354
24DCodes billed358
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 582,012 | $23.16M | |
| 2019 | 525,997 | $22.22M | |
| 2020 | 369,816 | $15.33M | |
| 2021 | 339,984 | $11.17M | |
| 2022 | 361,496 | $12.61M | |
| 2023 | 404,780 | $14.02M | |
| 2024incomplete | 219,269 | $7.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 40% | 153,645 | 137,292 | $42.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 143,824 | 131,028 | $22.90M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 60,705 | 51,889 | $19.37M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.8% | 243,907 | 205,077 | $4.00M |
| G0378 | Hospital observation service, per hour | 1.3% | 7,336 | 5,845 | $1.39M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 15,870 | 14,889 | $1.07M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 324,453 | 248,496 | $969K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 47,186 | 41,141 | $864K |
| 80053 | Comprehensive metabolic panel | <1% | 265,084 | 219,393 | $756K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 27,626 | 24,186 | $750K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 45,699 | 41,116 | $555K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,738 | 3,125 | $501K |
346 more codes
| 36415 | Collection of venous blood by venipuncture | <1% | 330,213 | $491K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 11,845 | $489K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 7,631 | $396K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,334 | $381K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 83,830 | $368K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,366 | $359K |
| 84484 | <1% | 44,705 | $354K | |
| 71045 | Radiologic examination, chest; single view | <1% | 35,308 | $291K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,656 | $287K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 1,681 | $256K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 37,098 | $215K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 21,680 | $195K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,124 | $189K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,758 | $188K |
| 93304 | <1% | 1,089 | $186K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,697 | $185K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,339 | $174K |
| 81025 | <1% | 88,078 | $171K | |
| 95812 | <1% | 2,104 | $160K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 37,322 | $148K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 349 | $145K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 151 | $144K |
| 92587 | <1% | 2,411 | $141K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 4,365 | $138K |
| 96367 | <1% | 3,599 | $128K | |
| 83690 | <1% | 35,769 | $124K | |
| 86900 | <1% | 7,149 | $114K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 630 | $113K |
| 36512 | <1% | 245 | $107K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,952 | $107K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,594 | $99K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,640 | $99K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,949 | $97K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 408 | $96K |
| 86902 | <1% | 785 | $93K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 210 | $89K |
| J0485 | Injection, belatacept, 1 mg | <1% | 738 | $79K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,108 | $78K |
| 86901 | <1% | 7,142 | $77K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,122 | $74K |
| 81001 | <1% | 92,879 | $74K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,676 | $71K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,730 | $64K |
| 92611 | <1% | 1,728 | $64K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 83 | $63K |
| 76770 | <1% | 1,322 | $63K | |
| 72082 | <1% | 1,337 | $62K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,054 | $60K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,592 | $59K |
| 83735 | <1% | 28,524 | $59K | |
| 87400 | <1% | 7,573 | $59K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,199 | $59K |
| 93320 | <1% | 1,796 | $58K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 874 | $58K |
| 86850 | <1% | 7,282 | $56K | |
| 93458 | <1% | 130 | $55K | |
| 74230 | <1% | 1,798 | $54K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 27 | $53K |
| 92567 | <1% | 4,172 | $50K | |
| 72170 | <1% | 1,646 | $49K | |
| 93325 | <1% | 4,140 | $47K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 155 | $47K |
| 83880 | <1% | 4,272 | $44K | |
| 80076 | <1% | 15,833 | $43K | |
| 74019 | <1% | 1,823 | $43K | |
| 93017 | <1% | 1,178 | $42K | |
| 93321 | <1% | 1,698 | $42K | |
| 29705 | <1% | 294 | $39K | |
| 85610 | <1% | 13,223 | $38K | |
| 84703 | <1% | 11,875 | $38K | |
| 80197 | <1% | 13,095 | $37K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 326 | $36K |
| 80061 | Lipid panel | <1% | 3,326 | $36K |
| 87799 | <1% | 5,360 | $35K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,131 | $33K |
| 92579 | <1% | 1,594 | $29K | |
| 73090 | <1% | 1,594 | $29K | |
| 82570 | <1% | 17,943 | $29K | |
| 93296 | <1% | 6,892 | $28K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,536 | $27K |
| 82962 | <1% | 15,627 | $27K | |
| 84439 | <1% | 3,297 | $27K | |
| 73110 | <1% | 1,303 | $26K | |
| 87497 | <1% | 3,223 | $25K | |
| 82947 | <1% | 15,509 | $24K | |
| 82728 | <1% | 3,904 | $24K | |
| 73070 | <1% | 1,551 | $24K | |
| 81003 | <1% | 31,231 | $23K | |
| 94010 | <1% | 755 | $23K | |
| 86140 | <1% | 4,401 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,237 | $23K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,127 | $21K |
| 82803 | <1% | 981 | $21K | |
| 73630 | <1% | 1,044 | $21K | |
| 97161 | <1% | 657 | $20K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 671 | $20K |
| 87807 | <1% | 1,852 | $20K | |
| 82330 | <1% | 1,775 | $20K | |
| 84100 | <1% | 17,922 | $19K | |
| 88342 | <1% | 317 | $19K | |
| 73590 | <1% | 913 | $18K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,214 | $18K |
| 73130 | <1% | 973 | $18K | |
| 54161 | <1% | 58 | $18K | |
| 73560 | <1% | 1,252 | $17K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,802 | $17K |
| 96415 | <1% | 737 | $17K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 36 | $17K |
| 85730 | <1% | 3,546 | $17K | |
| 74018 | <1% | 960 | $16K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 323 | $16K |
| 87040 | <1% | 1,490 | $16K | |
| 96417 | <1% | 637 | $15K | |
| 83970 | <1% | 739 | $14K | |
| 73610 | <1% | 965 | $14K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 653 | $13K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 2,213 | $13K |
| 83605 | <1% | 1,498 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,044 | $10K |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 85 | $10K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 272 | $10K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 355 | $10K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 448 | $10K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 68 | $9K |
| 47000 | <1% | 12 | $9K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 162 | $9K |
| 82565 | <1% | 1,729 | $9K | |
| 84156 | <1% | 13,504 | $9K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,283 | $9K |
| 82150 | <1% | 1,600 | $9K | |
| 83020 | <1% | 3,014 | $8K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 242 | $8K |
| 82610 | <1% | 773 | $8K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 175 | $7K |
| 90686 | <1% | 1,342 | $7K | |
| 82378 | <1% | 1,238 | $7K | |
| 83540 | <1% | 2,554 | $7K | |
| 84702 | <1% | 781 | $7K | |
| 85652 | <1% | 2,637 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 239 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,432 | $6K |
| 87186 | <1% | 716 | $6K | |
| 93289 | <1% | 1,697 | $6K | |
| 87077 | <1% | 621 | $6K | |
| 72100 | <1% | 1,272 | $6K | |
| 82043 | <1% | 2,247 | $6K | |
| 85045 | <1% | 5,734 | $6K | |
| 87070 | <1% | 680 | $5K | |
| 74022 | <1% | 924 | $5K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 18 | $5K |
| 99490 | Ccm add 20min | <1% | 8,876 | $5K |
| 74240 | <1% | 138 | $5K | |
| 76376 | <1% | 352 | $5K | |
| 80069 | <1% | 739 | $5K | |
| 82784 | <1% | 770 | $5K | |
| 31579 | <1% | 51 | $5K | |
| 36593 | <1% | 34 | $5K | |
| 84466 | <1% | 654 | $5K | |
| 77066 | Tomosynthesis, mammo | <1% | 104 | $5K |
| 70491 | <1% | 53 | $5K | |
| 77336 | <1% | 127 | $5K | |
| 85027 | <1% | 1,007 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,020 | $5K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 79 | $5K |
| 80050 | General health panel | <1% | 107 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,020 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 790 | $4K |
| 82044 | <1% | 1,403 | $4K | |
| 77061 | <1% | 66 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 145 | $4K |
| 96401 | <1% | 128 | $4K | |
| 83516 | <1% | 245 | $4K | |
| 90674 | <1% | 690 | $3K | |
| 77073 | <1% | 88 | $3K | |
| 96127 | <1% | 912 | $3K | |
| 73552 | <1% | 179 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,941 | $3K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 32 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,406 | $3K |
| 82248 | <1% | 1,310 | $3K | |
| 95811 | <1% | 13 | $3K | |
| 82977 | <1% | 1,170 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 30 | $2K |
| 92557 | <1% | 217 | $2K | |
| 51702 | <1% | 123 | $2K | |
| 87205 | <1% | 611 | $2K | |
| 93290 | <1% | 1,684 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 28,466 | $2K |
| 99406 | <1% | 277 | $2K | |
| 84145 | <1% | 97 | $2K | |
| 83550 | <1% | 1,292 | $2K | |
| 84132 | <1% | 439 | $2K | |
| 82607 | <1% | 429 | $2K | |
| 76536 | <1% | 56 | $2K | |
| 99152 | <1% | 1,468 | $2K | |
| 73030 | <1% | 175 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 152 | $2K |
| 70486 | <1% | 19 | $2K | |
| 72040 | <1% | 315 | $2K | |
| 82105 | <1% | 729 | $2K | |
| 93225 | <1% | 24 | $2K | |
| 86706 | <1% | 305 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 486 | $2K |
| 87522 | Neg quan hep c or qual rna | <1% | 170 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 222 | $2K |
| A9270 | Non-covered item or service | <1% | 9,232 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,307 | $2K |
| 83615 | <1% | 618 | $1K | |
| C9463 | Injection, aprepitant, 1 mg | <1% | 20 | $1K |
| 85379 | <1% | 350 | $1K | |
| 85014 | <1% | 825 | $1K | |
| 86364 | <1% | 291 | $1K | |
| 86300 | <1% | 209 | $1K | |
| C1769 | Guide wire | <1% | 1,257 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 55 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,969 | $1K |
| 93226 | <1% | 12 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,499 | $1K |
| 86832 | <1% | 31 | $1K | |
| 90677 | <1% | 14 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 26 | $1K |
| 94644 | <1% | 70 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,837 | $1K |
| 82746 | <1% | 276 | $1K | |
| 86833 | <1% | 31 | $1K | |
| 82550 | <1% | 273 | $999.28 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,638 | $956.25 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 295 | $847.09 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 30 | $821.64 |
| 97597 | <1% | 47 | $820.33 | |
| 31575 | <1% | 49 | $779.89 | |
| 87081 | <1% | 132 | $769.47 | |
| 87147 | <1% | 111 | $712.54 | |
| 73060 | <1% | 49 | $650.00 | |
| 76642 | <1% | 17 | $642.08 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,363 | $640.82 |
| 70360 | <1% | 69 | $629.00 | |
| 93971 | <1% | 74 | $603.10 | |
| 87634 | <1% | 40 | $568.62 | |
| 84295 | <1% | 97 | $552.92 | |
| 90715 | <1% | 82 | $515.92 | |
| 82657 | <1% | 29 | $501.50 | |
| 92555 | <1% | 217 | $431.76 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 52 | $425.15 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 133 | $422.93 |
| 88341 | <1% | 30 | $391.30 | |
| 90662 | <1% | 158 | $387.16 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 59 | $372.05 |
| 92550 | <1% | 92 | $362.98 | |
| 92552 | <1% | 71 | $312.00 | |
| 94664 | <1% | 63 | $310.00 | |
| 84550 | <1% | 80 | $302.27 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 43 | $282.85 |
| G0008 | Administration of influenza virus vaccine | <1% | 1,721 | $269.72 |
| 93925 | <1% | 24 | $269.63 | |
| 86665 | <1% | 90 | $254.40 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 68 | $245.38 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,514 | $240.90 |
| 90732 | <1% | 16 | $240.87 | |
| 86803 | <1% | 88 | $239.16 | |
| 86644 | <1% | 90 | $238.35 | |
| 90837 | Psychotherapy session, about an hour | <1% | 13 | $229.50 |
| 99153 | Mod sedat endo service >5yrs | <1% | 469 | $227.38 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 829 | $205.25 |
| 86704 | <1% | 90 | $199.98 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,622 | $177.22 |
| 86708 | <1% | 101 | $172.48 | |
| 87102 | <1% | 12 | $164.13 | |
| 80177 | <1% | 13 | $161.92 | |
| 77080 | <1% | 12 | $155.08 | |
| 92582 | <1% | 42 | $153.51 | |
| 86923 | <1% | 15 | $151.90 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 50 | $147.10 |
| 83935 | <1% | 16 | $145.95 | |
| 84681 | <1% | 63 | $143.63 | |
| 86709 | <1% | 68 | $132.21 | |
| 86592 | <1% | 96 | $130.05 | |
| 93299 | <1% | 19 | $128.00 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 38 | $127.68 |
| 84520 | <1% | 25 | $123.86 | |
| 97802 | <1% | 1,134 | $120.52 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 13 | $117.67 |
| 85018 | <1% | 83 | $115.27 | |
| 87340 | <1% | 68 | $106.49 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 424 | $103.25 |
| C1733 | Catheter, electrophysiology, diagnostic/ablation, other than 3d or vector mapping, other than cool-tip | <1% | 147 | $89.70 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 720 | $81.56 |
| 97162 | <1% | 14 | $80.80 | |
| 86152 | <1% | 20 | $80.77 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 53 | $80.28 |
| 83037 | <1% | 18 | $80.26 | |
| 70210 | <1% | 15 | $79.97 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,204 | $78.15 |
| 93288 | <1% | 36 | $63.54 | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 17 | $57.42 |
| 86705 | <1% | 18 | $57.40 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 105 | $51.52 |
| 93922 | <1% | 49 | $47.32 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 14 | $45.75 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 268 | $41.98 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 111 | $41.97 |
| J1815 | Injection, insulin, per 5 units | <1% | 21 | $41.63 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 515 | $36.54 |
| 80074 | <1% | 17 | $32.42 | |
| 36416 | <1% | 106 | $31.57 | |
| 92583 | <1% | 20 | $28.80 | |
| 90653 | <1% | 16 | $19.68 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 58 | $19.49 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 19 | $16.65 |
| J3490 | Unclassified drugs | <1% | 903 | $14.32 |
| 90661 | <1% | 33 | $10.33 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 130 | $8.80 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 107 | $3.02 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 240 | $2.47 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 54 | $1.30 |
| 96376 | <1% | 252 | $0.49 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 352 | $0.00 |
| 90694 | 0% | 157 | $0.00 | |
| 88304 | 0% | 26 | $0.00 | |
| 36591 | 0% | 139 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 135 | $0.00 |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 137 | $0.00 |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 0% | 63 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 82 | $0.00 |
| 99457 | 0% | 16 | $0.00 | |
| 94760 | 0% | 17 | $0.00 | |
| 88307 | 0% | 12 | $0.00 | |
| 99454 | 0% | 29 | $0.00 | |
| 41899 | Unlisted procedure, dentoalveolar structures | 0% | 19 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 14 | $0.00 |
| 96368 | 0% | 22 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 14 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 14 | $0.00 |
| 97803 | 0% | 807 | $0.00 | |
| 92504 | 0% | 781 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 14 | $0.00 |
| 76937 | 0% | 28 | $0.00 | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 12 | $0.00 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0% | 35 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 68 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 42 | $0.00 |
| 77012 | 0% | 12 | $0.00 | |
| A4600 | Sleeve for intermittent limb compression device, replacement only, each | 0% | 30 | $0.00 |
| 90714 | 0% | 20 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 14 | $0.00 |
| 88313 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLANE, CHARLES (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| KC Companies of Sandstone Inc/Sandstone Golden Horizons | Sandstone, MN | $1.40M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.